Key Development
Brelovitug has cleared an important Phase 3 hurdle in chronic hepatitis delta — but the market it may enter has changed dramatically in only a few months.
On September 28, 2026, Mirum Pharmaceuticals reported that the Phase 3 AZURE-1 study met its primary endpoint in chronic hepatitis delta virus infection. At Week 24, the composite endpoint of virologic response plus ALT normalization was achieved by 56% of patients receiving brelovitug 300 mg weekly and 45% receiving 900 mg every four weeks, versus 0% in the delayed-treatment group. Virologic response alone reached 86% and 85%, while 17% in each treatment arm had HDV RNA below quantification with target not detected.
Brelovitug is a fully human monoclonal antibody targeting HBsAg, the surface antigen shared by the HBV-HDV viral system. It is designed to neutralize viral particles and facilitate clearance of HBsAg-containing particles from circulation. Mirum obtained worldwide rights through its acquisition of Bluejay Therapeutics, completed in January 2026.
Why It Matters
- HDV is rare but unusually aggressive. It occurs only in people infected with HBV and can rapidly drive fibrosis, cirrhosis, liver cancer, hepatic failure and death.
- Brelovitug no longer enters an untreated market. FDA approved Gilead’s Hepcludex (bulevirtide) in May 2026 as the first U.S. treatment for chronic HDV.
- Dosing could become a meaningful differentiator. Brelovitug is being studied as a once-weekly or once-every-four-weeks injection, versus daily dosing for Hepcludex.
- Topline tolerability appears favorable. No grade ≥3 adverse events were reported in either brelovitug arm through Week 24, and no patients discontinued study treatment because of adverse events.
Healthcare Insight Analysis
Healthcare Insight believes AZURE-1 should be interpreted differently from how the same result would have been viewed at the end of 2025.
When Mirum agreed to acquire Bluejay in a transaction worth up to roughly $820 million, there was still no FDA-approved HDV therapy in the United States.
That changed in May 2026.
Hepcludex became the first FDA-approved HDV treatment. In its pivotal MYR301 study, 48% of patients achieved the composite endpoint of virologic response plus ALT normalization at Week 48, versus 2% with delayed treatment.
Brelovitug therefore cannot win merely by proving that HDV RNA declines.
It must build a differentiated treatment profile.
The first possible advantage is treatment burden.
HDV is a chronic disease that may require prolonged therapy. The difference between a daily injection and weekly or monthly administration could materially influence persistence, particularly once treatment moves outside specialist centers into long-term routine care.
The second issue is depth of suppression.
Although 85–86% of AZURE-1 patients met the study’s virologic-response definition at Week 24, only 17% had HDV RNA below quantification with target not detected. Phase 2b data suggest suppression deepens with longer exposure, making the 48-week Phase 3 trajectory especially important.
The third and ultimately more important issue is clinical translation.
Both brelovitug and Hepcludex currently rely heavily on surrogate endpoints — HDV RNA reduction and ALT normalization.
FDA’s approval of Hepcludex carries a postmarketing requirement to determine whether those improvements actually reduce cirrhosis, hepatic decompensation, transplantation, hepatocellular carcinoma and liver-related death over years of follow-up.
That requirement defines where the entire HDV field must ultimately go.
The winning drug may therefore not simply be the one with the highest Week-24 viral-response percentage. It may be the therapy that delivers deep suppression, tolerable chronic use, adherence-friendly dosing and eventually better liver outcomes.
Market Implications
Mirum: AZURE-1 materially de-risks the Bluejay acquisition, but positive AZURE-4 data remain important for the planned U.S. BLA in the first half of 2027.
Gilead/Hepcludex: retains meaningful first-mover advantage, but convenience could become a competitive pressure if brelovitug reaches the market.
Hepatology providers: HDV care may move from scarcity of options toward treatment selection based on disease stage, adherence, viral depth and durability.
Payers: value assessment will increasingly focus on sustained response and prevention of cirrhosis, HCC and transplantation rather than short-term viral decline alone.
ANALYTICAL MATRIX
| Dimension | Brelovitug Today | Opportunity | Key Risk |
| Efficacy | 56% / 45% composite response at Week 24 | Deeper suppression over time | No hard-outcome evidence |
| Dosing | Weekly or every four weeks | Lower treatment burden | Real-world persistence unknown |
| Safety | No grade ≥3 AEs in treatment arms at Week 24 | Suitable for chronic use | Longer-term safety needed |
| Competition | Post-Hepcludex launch | Differentiate through convenience | Competitor first-mover advantage |
| Regulatory | Positive AZURE-1 | BLA targeted H1 2027 | AZURE-4 remains critical |
The next two signals are the AZURE-4 Phase 3 readout and whether longer treatment materially increases the proportion of patients with fully suppressed HDV RNA.
If both are positive, brelovitug could become more than America’s second HDV therapy. It could shift the market toward a more demanding standard: not simply reducing the virus, but sustaining deep control with a regimen patients can realistically remain on for years.